Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Group B-Sun Yat-sen University-type 2 diabetes mellitus
- Development stage
- Unknown
- Lead developer
- Sun Yat-sen University
- Modality
- Small Molecules, Peptides
- Administration
- Oral, Subcutaneous
01
Overview
Group B-Sun Yat-sen University-type 2 diabetes mellitus refers to the standard-of-care treatment arm in a Phase 3 clinical trial (NCT06165458) sponsored by Sun Yat-sen University for patients with newly diagnosed type 2 diabetes mellitus. This regimen follows a stepwise intensification protocol, beginning with metformin monotherapy (or linagliptin if metformin is contraindicated). If glycemic targets are not achieved, the protocol dictates the sequential addition of the SGLT2 inhibitor empagliflozin, followed by the GLP-1 receptor agonist semaglutide, and finally basal insulin therapy. This arm serves as the active comparator to evaluate the efficacy of traditional sequential therapy against early intensive triple combination therapy in achieving diabetes remission and improving beta-cell function.
- Other names
- metformin-based stepwise therapymetformin-based treatment
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)DPP-4 (Dipeptidyl Peptidase-IV)GLP1R (GLP-1R)INSR (Insulin receptor)SGLT2 (Sodium-glucose cotransporter protein subunit 2)
Beyond the preview
Go deeper on Group B-Sun Yat-sen University-type 2 diabetes mellitus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Group B-Sun Yat-sen University-type 2 diabetes mellitus.